Clinical trials in COVID-19 management & prevention: A meta-epidemiological study examining methodological quality
暂无分享,去创建一个
A. Agarwal | S. Murthy | B. Rochwerg | S. Fernando | F. Lamontagne | K. Burns | T. Agoritsas | J. Penn | R. Brignardello-Petersen | D. Zeraatkar | F. Foroutan | R. Siemieniuk | L. Ge | L. Ge | P. Vandvik | J. Yepes-Nuñez | K. Honarmand | A. Agarwal | J. Bartoszko | Z. Ye | S. Fernando | M. A. Jiminez-Mora | P. Vandvik | Z. Ye | S. Murthy | R. Siemieniuk | Karen Burns | Mario A. Jiménez-Mora | J. Penn
[1] F. Pourfarzi,et al. The Impact of Colchicine on COVID-19 patients: A Clinical Trial Study , 2020, Mediterranean journal of rheumatology.
[2] Bruno Luís de Castro Araujo. Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 , 2021, Annals of Internal Medicine.
[3] J. Ge,et al. A Randomized, Single-Blind, Group Sequential, Active-Controlled Study to Evaluate the Clinical Efficacy and Safety of α-Lipoic Acid for Critically Ill Patients With Coronavirus Disease 2019 (COVID-19) , 2020, Frontiers in Medicine.
[4] G. Guyatt,et al. Patient-important outcomes reported in clinical studies of pharmacologic treatments for covid-19: A protocol of a meta-epidemiological study , 2020 .
[5] Jan A. Roth,et al. The worldwide clinical trial research response to the COVID-19 pandemic - the first 100 days , 2020, F1000Research.
[6] Reza Hajizadeh,et al. The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial , 2020, BMC Infectious Diseases.
[7] Inge Christoffer Olsen,et al. A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics , 2020, Nature Communications.
[8] R. Malekzadeh,et al. Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results , 2020, medRxiv.
[9] J. Nielsen,et al. Combined metabolic cofactor supplementation accelerates recovery in mild-to-moderate COVID-19 , 2020, medRxiv.
[10] Jan A. Roth,et al. The worldwide clinical trial research response to the COVID-19 pandemic - the first 100 days. , 2020, F1000Research.
[11] Jennifer L. Bell,et al. Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial , 2020, The Lancet.
[12] B. Abella,et al. Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers , 2020, JAMA internal medicine.
[13] Ke Wang,et al. Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size , 2020, Biomedicine & Pharmacotherapy.
[14] M. El-Sayed,et al. A Randomized Controlled Study Of Favipiravir Vs Hydroxychloroquine In COVID-19 Management: What Have We Learned So Far? , 2020 .
[15] P. van Paassen,et al. Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial , 2020, The Lancet Rheumatology.
[16] Jonathan S. Austrian,et al. Treating COVID-19 With Hydroxychloroquine (TEACH): A Multicenter, Double-Blind Randomized Controlled Trial in Hospitalized Patients , 2020, Open forum infectious diseases.
[17] J. Marchini,et al. Double-blind, randomized, placebo-controlled trial with N-acetylcysteine for treatment of severe acute respiratory syndrome caused by COVID-19 , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[18] A. Lahiri,et al. Nature and dimensions of the cytokine storm and its attenuation by convalescent plasma in severe COVID-19 , 2020, medRxiv.
[19] Felipe García,et al. Pre-exposure prophylaxis with hydroxychloroquine for COVID-19: initial results of a double-blind, placebo-controlled randomized clinical trial , 2020 .
[20] S. Tajima,et al. A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19 , 2020, Antimicrobial Agents and Chemotherapy.
[21] Dong Zhao,et al. Treatment of COVID-19 Patients with Prolonged Post-Symptomatic Viral Shedding with Leflunomide -- a Single-Center, Randomized, Controlled Clinical Trial , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[22] A. Pazin-Filho,et al. Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID) , 2020, Thrombosis Research.
[23] J. Balko,et al. Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial , 2020, medRxiv.
[24] J. Myburgh,et al. An evaluation of the quality and impact of the global research response to the COVID‐19 pandemic , 2020, The Medical journal of Australia.
[25] A. Pizarro,et al. Early Anti-SARS-CoV-2 Convalescent Plasma in Patients Admitted for COVID-19: A Randomized Phase II Clinical Trial , 2020, medRxiv.
[26] S. Najafizadeh,et al. Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial , 2020, European Respiratory Journal.
[27] H. Keyvani,et al. Effect of Arbidol on COVID-19: A Randomized Controlled Trial , 2020 .
[28] Y. Perera,et al. Treatment with an Anti-CK2 Synthetic Peptide Improves Clinical Response in COVID-19 Patients with Pneumonia. A Randomized and Controlled Clinical Trial , 2020, medRxiv.
[29] Naweed I Chowdhury,et al. Interim analysis of an open‐label randomized controlled trial evaluating nasal irrigations in non‐hospitalized patients with coronavirus disease 2019 , 2020, International forum of allergy & rhinology.
[30] M. Martinez-Fierro,et al. Patient-Reported Health Outcomes After Treatment of COVID-19 with Nebulized and/or Intravenous Neutral Electrolyzed Saline Combined with Usual Medical Care Versus Usual Medical care alone: A Randomized, Open-Label, Controlled Trial. , 2020, Research square.
[31] W. Guan,et al. Effect of Recombinant Human Granulocyte Colony-Stimulating Factor for Patients With Coronavirus Disease 2019 (COVID-19) and Lymphopenia: A Randomized Clinical Trial. , 2020, JAMA internal medicine.
[32] Shashank Srivastava,et al. Convalescent plasma in the management of moderate COVID-19 in India: An open-label parallel-arm phase II multicentre randomized controlled trial (PLACID Trial) , 2020, medRxiv.
[33] M. Zhang,et al. Efficacy and Safety of Triazavirin Therapy for Coronavirus Disease 2019: A Pilot Randomized Controlled Trial , 2020, Engineering.
[34] Á. Avezum,et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial , 2020, The Lancet.
[35] G. Guyatt,et al. A living WHO guideline on drugs for covid-19 , 2020, BMJ.
[36] Wenwu Zhang,et al. Bromhexine Hydrochloride Tablets for the Treatment of Moderate COVID‐19: An Open‐Label Randomized Controlled Pilot Study , 2020, Clinical and translational science.
[37] Á. Avezum,et al. Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial. , 2020, JAMA.
[38] D. Annane,et al. Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19: A Randomized Clinical Trial. , 2020, JAMA.
[39] Christopher M. Horvat,et al. Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial. , 2020, JAMA.
[40] I. Douglas,et al. Tocilizumab in Hospitalized Patients With COVID-19 Pneumonia , 2020, medRxiv.
[41] J. Alcamí,et al. Convalescent Plasma for COVID-19: A multicenter, randomized clinical trial , 2020, medRxiv.
[42] R. Bouillon,et al. “Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study” , 2020, The Journal of Steroid Biochemistry and Molecular Biology.
[43] X. Yao,et al. Tocilizumab Ameliorates the Hypoxia in COVID-19 Moderate Patients with Bilateral Pulmonary Lesions: A Randomized, Controlled, Open-Label, Multicenter Trial , 2020 .
[44] M. Yekaninejad,et al. Interferon β-1b in treatment of severe COVID-19: A randomized clinical trial , 2020, International Immunopharmacology.
[45] N. Manafi,et al. Safety and effectiveness of azithromycin in patients with COVID-19: An open-label randomised trial , 2020, International Journal of Antimicrobial Agents.
[46] O. Tsang,et al. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. , 2020, JAMA.
[47] T. Tagaev,et al. Efficacy of umifenovir in the treatment of mild and moderate COVID-19 patients , 2020 .
[48] A. Davarpanah,et al. Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial , 2020, The Journal of antimicrobial chemotherapy.
[49] S. Merat,et al. Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial , 2020, The Journal of antimicrobial chemotherapy.
[50] S. Abd-Elsalam,et al. Hydroxychloroquine in the Treatment of COVID-19: A Multicenter Randomized Controlled Study , 2020, The American journal of tropical medicine and hygiene.
[51] L. Velloso,et al. Pharmacological inhibition of the kinin-kallikrein system in severe COVID-19 A proof-of-concept study , 2020, medRxiv.
[52] Q. Bassat,et al. Methylprednisolone as Adjunctive Therapy for Patients Hospitalized With COVID-19 (Metcovid): A Randomised, Double-Blind, Phase IIb, Placebo-Controlled Trial , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[53] F. Pelorosso,et al. Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report. , 2020, medRxiv.
[54] F. Cunha,et al. Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial , 2020, medRxiv.
[55] Z. Meng,et al. High-dose vitamin C infusion for the treatment of critically ill COVID-19 , 2020 .
[56] N. Savchuk,et al. AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[57] P. Niu,et al. SARS-CoV-2 clearance in COVID-19 patients with Novaferon treatment: A randomized, open-label, parallel-group trial , 2020, International Journal of Infectious Diseases.
[58] Géric Maura,et al. TITLE PAGE Title: Effect and safety of combination of interferon alpha-2b and gamma or interferon alpha-2b for negativization of SARS-CoV-2 viral RNA. Preliminary results of a randomized controlled clinical trial. Authors: *Idelsis Esquivel-Moynelo I , 2020 .
[59] G. Guyatt,et al. Drug treatments for covid-19: living systematic review and network meta-analysis , 2020, BMJ.
[60] F. Shan,et al. A clinical pilot study on the safety and efficacy of aerosol inhalation treatment of IFN-κ plus TFF2 in patients with moderate COVID-19 , 2020, EClinicalMedicine.
[61] C. Tebé,et al. A Cluster-Randomized Trial of Hydroxychloroquine as Prevention of Covid-19 Transmission and Disease , 2020, medRxiv.
[62] R. Kullar,et al. Intravenous Immunoglobulin (IVIG) Significantly Reduces Respiratory Morbidity in COVID-19 Pneumonia: A Prospective Randomized Trial , 2020, medRxiv.
[63] Á. Avezum,et al. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19 , 2020, The New England journal of medicine.
[64] S. Safiri,et al. Effect of bromhexine on clinical outcomes and mortality in COVID-19 patients: A randomized clinical trial , 2020, BioImpacts : BI.
[65] S. Lofgren,et al. Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 , 2020, Annals of Internal Medicine.
[66] K. Stauderman,et al. Auxora versus standard of care for the treatment of severe or critical COVID-19 pneumonia: results from a randomized controlled trial , 2020, Critical Care.
[67] Jennifer L. Bell,et al. Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial. , 2020, medRxiv.
[68] Z. Ren,et al. A Randomized, Open‐Label, Controlled Clinical Trial of Azvudine Tablets in the Treatment of Mild and Common COVID‐19, a Pilot Study , 2020, Advanced science.
[69] Yaokai Chen,et al. No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coronavirus Disease 2019: Results of a Randomized, , 2020, Frontiers in Pharmacology.
[70] M. Yekaninejad,et al. A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment of Severe COVID-19 , 2020, Antimicrobial Agents and Chemotherapy.
[71] C. Hsiao,et al. A multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate coronavirus disease 2019 (COVID-19) , 2020, medRxiv.
[72] R. Dal-Ré,et al. Waste in COVID-19 clinical trials conducted in western Europe , 2020, European Journal of Internal Medicine.
[73] Honglin Li,et al. A Small-Scale Medication of Leflunomide as a Treatment of COVID-19 in an Open-Label Blank-Controlled Clinical Trial , 2020, Virologica Sinica.
[74] D. Hsiehchen,et al. Deficiencies in the Designs and Interventions of COVID-19 Clinical Trials , 2020, Med.
[75] M. M. van der Eerden,et al. Convalescent Plasma for COVID-19. A randomized clinical trial , 2020, medRxiv.
[76] S. Hosseinimehr,et al. Febuxostat therapy in outpatients with suspected COVID‐19: A clinical trial , 2020, International journal of clinical practice.
[77] Jennifer L. Bell,et al. Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report , 2020, medRxiv.
[78] Xiang Chen,et al. Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of COVID-19: a prospective open-label randomized controlled study , 2020, medRxiv.
[79] J. Riancho,et al. GLUCOCOVID: A controlled trial of methylprednisolone in adults hospitalized with COVID-19 pneumonia , 2020, medRxiv.
[80] Zheng-Yang Shi,et al. Recombinant Super-Compound Interferon (rSIFN-co) Versus Interferon Alfa in the Treatment of Moderate-to-Severe COVID-19: A Multicentre, Randomised, Phase 2 Trial , 2020 .
[81] H. Keskin,et al. The comparison of the effectiveness of lincocin® and azitro® in the treatment of covid-19-associated pneumonia: A prospective study. , 2020, Journal of population therapeutics and clinical pharmacology = Journal de la therapeutique des populations et de la pharmacologie clinique.
[82] Emily G McDonald,et al. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19 , 2020, The New England journal of medicine.
[83] L. Ren,et al. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. , 2020, JAMA.
[84] G. Dangas,et al. Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019 , 2020, JAMA network open.
[85] J. Segal,et al. Characteristics of registered clinical trials assessing treatments for COVID-19: a cross-sectional analysis , 2020, BMJ Open.
[86] R. Bruno,et al. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 , 2020, The New England journal of medicine.
[87] Jing Liu,et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial , 2020, Journal of Allergy and Clinical Immunology.
[88] B. Ibáñez,et al. Ramipril in High-Risk Patients With COVID-19 , 2020, Journal of the American College of Cardiology.
[89] L. Dodd,et al. Remdesivir for the Treatment of Covid-19 — Final Report , 2020, The New England journal of medicine.
[90] J. Qu,et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial , 2020, BMJ.
[91] T. Hoffmann,et al. Waste in covid-19 research , 2020, BMJ.
[92] T. Liang,et al. Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial , 2020, European Journal of Pharmaceutical Sciences.
[93] Kwok-Hung Chan,et al. Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial , 2020, The Lancet.
[94] Changming Niu,et al. Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells , 2020, Stem Cell Research & Therapy.
[95] Yi Wang,et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial , 2020, The Lancet.
[96] W. Alhazzani,et al. COVID-19 coronavirus research has overall low methodological quality thus far: case in point for chloroquine/hydroxychloroquine , 2020, Journal of Clinical Epidemiology.
[97] Lichuan Zhang,et al. Pulmonary radiological change of COVID-19 patients with 99mTc-MDP treatment , 2020, medRxiv.
[98] Q. Bassat,et al. Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. , 2020, JAMA network open.
[99] J. Marshall,et al. Misinformation During the Coronavirus Disease 2019 Outbreak: How Knowledge Emerges From Noise , 2020, Critical care explorations.
[100] Duanqing Pei,et al. Treating COVID-19 with Chloroquine , 2020, Journal of molecular cell biology.
[101] Zhan Zhang,et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial , 2020, medRxiv.
[102] Xilong Deng,et al. An exploratory randomized controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI) , 2020, medRxiv.
[103] Bo Chen,et al. Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial , 2020, medRxiv.
[104] Yuan Wei,et al. A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 , 2020, The New England journal of medicine.
[105] Shigui Yang,et al. Systematic review of the registered clinical trials for coronavirus disease 2019 (COVID-19) , 2020, Journal of Translational Medicine.
[106] Nobuhiro,et al. A prospective, randomized, open-label trial of early versus late favipiravir in hospitalized patients with COVID-19 , 2020 .
[107] B. Abella,et al. Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical Trial , 2020 .
[108] J. Ioannidis,et al. Industry-funded versus non-profit-funded critical care research: a meta-epidemiological overview , 2018, Intensive Care Medicine.
[109] Byron C. Wallace,et al. Machine learning for identifying Randomized Controlled Trials: An evaluation and practitioner's guide , 2018, Research synthesis methods.
[110] A. F. Delgado,et al. The association of funding source on effect size in randomized controlled trials: 2013-2015 - a cross-sectional survey and meta-analysis. , 2017 .
[111] Anna Falk Delgado,et al. The association of funding source on effect size in randomized controlled trials: 2013–2015 – a cross-sectional survey and meta-analysis , 2017, Trials.
[112] B. Vandermeer,et al. A meta-epidemiological study to examine the association between bias and treatment effects in neonatal trials. , 2014, Evidence-based child health : a Cochrane review journal.
[113] P. Funch‐jensen,et al. Randomized clinical trial: inhibition of the TRPV1 system in patients with nonerosive gastroesophageal reflux disease and a partial response to PPI treatment is not associated with analgesia to esophageal experimental pain , 2013, Scandinavian journal of gastroenterology.
[114] Zhongheng Zhang,et al. Small studies may overestimate the effect sizes in critical care meta-analyses: a meta-epidemiological study , 2013, Critical Care.
[115] Ross J. Harris,et al. Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies. , 2012, Health technology assessment.
[116] Karina D. Torralba,et al. Association of industry funding with the outcome and quality of randomized controlled trials of drug therapy for rheumatoid arthritis. , 2012, Arthritis and rheumatism.
[117] D. Moher,et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement , 2009, BMJ : British Medical Journal.
[118] D. Moher,et al. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement , 2009, BMJ : British Medical Journal.
[119] Zoran Bursac,et al. Purposeful selection of variables in logistic regression , 2008, Source Code for Biology and Medicine.
[120] Douglas G Altman,et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study , 2008, BMJ : British Medical Journal.
[121] T. Carmody,et al. An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia. , 2004, Controlled clinical trials.
[122] D. Cook,et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? , 1998, The Lancet.
[123] R. J. Hayes,et al. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. , 1995, JAMA.